-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ibrahim erlotinib in non-treated (TN) and relapsed / refractory (R / R) chronic lymphocytic leukemia (CLL) patients were active, including those unmutated immune immunoglobulin heavy chain variable region (IGHV ) And TP53 interrupted patients
Ibrutinib Immunization
In order to study the dynamics of TP53 large mutations under the treatment of ibrutinib, a foreign expert team conducted deep sequencing and longitudinal TP53 monitoring of patients treated with CLL
In order to study the dynamics of TP53 large mutations under the treatment of ibrutinib, a foreign expert team conducted deep sequencing and longitudinal TP53 monitoring of patients treated with CLL
In TN and R/RCLL patients with TP53 mutations, ibrutinib seems to reduce the number and complexity of major and minor mutations, because most mutations are reduced or undetectable, and one-third of mutations remain stable
After more than 2 years of long-term follow-up, up to 44 months, the data adds to the preliminary findings of the general stability of TP53 subclones during early treatment, and supports the view that there is no specific positive selection of TP53 mutations under ibrutinib
The emergence of new mutations proved to be a special event, mainly confined to R/R patients who showed more complex mutation structures from the beginning, indicating the potential impact of the previous CIT
In summary, in CLL patients with TP53 mutations, ibrutinib in any treatment regimen reduces the complexity of TP53 at least within the first few years of treatment, and unlike CIT, it does not affect the existing TP53.
In CLL patients with TP53 mutations, ibrutinib in any treatment regimen reduces the complexity of TP53 for at least the first few years of treatment, and unlike CIT, it does not impose positive selection on existing TP53 mutant clones.
Cafforio L, Raponi S, Cappelli LV, Ilari C, Soscia R, De Propris MS, Mariglia P, Rigolin GM, Bardi A, Peragine N, Piciocchi A, Arena V, Mauro FR, Cuneo A, Guarini A, Foa R, Del Giudice I.
Cafforio L, Raponi S, Cappelli LV, Ilari C, Soscia R, De Propris MS, Mariglia P, Rigolin GM, Bardi A, Peragine N, Piciocchi A, Arena V, Mauro FR, Cuneo A, Guarini A, Foa R, Del Giudice I.
Leave a message here
